Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal conjugate vaccine, groups A, C, W-135, Y
- Development stage
- Unknown
- Lead developer
- Lanzhou Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent meningococcal conjugate vaccine developed by the Lanzhou Institute of Biological Products for the prevention of invasive meningococcal disease. The vaccine is a lyophilized (freeze-dried) formulation containing capsular polysaccharide antigens from Neisseria meningitidis serogroups A, C, Y, and W-135, each conjugated to a carrier protein to enhance immunogenicity, particularly in infants and young children. By inducing the production of serogroup-specific bactericidal antibodies, the vaccine provides protection against meningitis and septicemia caused by these four serogroups. It has been evaluated in Phase 3 clinical trials (e.g., CTR20201077 and NCT02481232) to assess its safety and immunogenicity across various age groups, demonstrating non-inferiority to established meningococcal vaccines.
- Other names
- lyophilized Group ACYW135 Meningococcal Conjugate VaccineACYW135 meningococcal conjugate vaccineACYW-135 meningococcal conjugate vaccineACYW 135 meningococcal conjugate vaccineGroup ACYW135 meningococcal conjugate vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal conjugate vaccine, groups A, C, W-135, Y.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal conjugate vaccine, groups A, C, W-135, Y.